跳至主要内容
临床试验/NCT00697450
NCT00697450已完成不适用

Observational Study Evaluating the Body Weight Progress During the Treatment With Insulin Detemir (Levemir®) in Type 2 Patients, Previously Treated With Other Basal Insulins

Novo Nordisk A/S1 个研究点 分布在 1 个国家目标入组 206 人开始时间: 2008年7月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
206
试验地点
1
主要终点
Weight effect

研究概览

简要总结

This study is conducted in Europe. Observational study evaluating the body weight progress during the treatment with insulin detemir (Levemir®) in Type 2 patients, previously treated with other basal insulins

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Type 2 diabetes
  • Current treatment with insulin NPH or glargine
  • The selection of the subjects will be at the discretion of the individual physician

排除标准

  • Current treatment with insulin detemir
  • Previous enrolment in this study
  • Hypersensitivity to insulin detemir or to any of the excipients.
  • Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 12 months

研究组 & 干预措施

All participants

干预措施: insulin detemir (Drug)

结局指标

主要结局

Weight effect

时间窗: 12 months prior to and 12 months after detemir treatment.

次要结局

  • Improvement in FPG levels(12 months prior and 12 months after detemir treatment)
  • Improvement in HbA1c levels(12 months prior and 12 months after detemir treatment)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验